市場調査レポート

がん胎児性抗原 (CEA) 市場分析:応用別 (大腸がん、膵臓がん、卵巣がん、乳がん、甲状腺がん) 、セグメント別の予測

Carcinoembryonic Antigen (CEA) Market Analysis by Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer) and Segment Forecasts To 2022

発行 Grand View Research, Inc. 商品コード 342363
出版日 ページ情報 英文 74 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
がん胎児性抗原 (CEA) 市場分析:応用別 (大腸がん、膵臓がん、卵巣がん、乳がん、甲状腺がん) 、セグメント別の予測 Carcinoembryonic Antigen (CEA) Market Analysis by Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer) and Segment Forecasts To 2022
出版日: 2015年06月01日 ページ情報: 英文 74 Pages
概要

世界のがん胎児性抗原 (CEA) 市場は、2020年までに25億6千万米ドルに達する見込みです。他のバイオマーカーと組み合わせて使用できる、新規のバイオマーカーの開発に関する一定の技術の進歩によって、使用率が牽引されると予測されています。

当レポートでは、世界のがん胎児性抗原 (CEA) 市場に調査分析し、応用別、地域別の見通しのほか、主要企業について、体系的な情報を提供しています。

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 がん胎児性抗原 (CEA) 産業の見通し

  • 市場区分
  • 市場規模と成長見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 優先される主要機会
  • 産業分析
  • PESTEL分析

第4章 がん胎児性抗原 (CEA) の応用別の見通し

  • 応用別
  • 大腸がん
  • 膵臓がん
  • 卵巣がん
  • 乳がん
  • 甲状腺がん
  • その他

第5章 がん胎児性抗原 (CEA) の地域別の見通し

  • 地域別
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • スペイン
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
  • ラテンアメリカ
    • メキシコ
    • ブラジル
  • 中東・アフリカ
    • 南アフリカ

第6章 競合情勢

  • 企業プロファイル (企業概要、財務実績、製品ベンチマーク、戦略的構想)
    • Quest Diagnostics
    • Roche Diagnostics
    • Abbott Diagnostics
    • GenWay Biotech Inc.
    • Correlogic Systems, Inc.

図表

目次

Global carcinoembryonic antigen market is expected to reach USD 2.56 Billion by 2022. Constant technological advancements pertaining to the development of novel biomarkers which can be used in combination with other biomarkers is expected to boost usage rates over the forecast period. Furthermore, the increasing prevalence of cancer is expected to heighten the demand for effective diagnostic tools. According to the WHO estimates in 2012, global cancer incidences were nearly 14.1 million, which include 6.7 million female patients and 7.4 million male patients. Increasing demand for minimally invasive diagnostics procedures is also expected to play a vital role in determining market growth. Key advantages associated with minimally invasive diagnostics procedures include elevated patient satisfaction levels as they entail minor incision wounds. In addition, these procedures involve relatively lesser hospital stays and therefore, are economically viable and involve fewer post procedure complications.

Further key findings from the study suggest:

Colorectal cancer was one of the largest revenue generating application segment of the carcinoembryonic antigen market and was estimated at USD 639.65 million in 2014. Increasing prevalence of colorectal cancer and usage of carcinoembryonic antigen tests at various stages is one of the critical factors accounting for its large share. For instance, in 2012, new cases of colorectal cancer were estimated to be over 93,000 and death due to colorectal cancer is expected to be over 49,700 in the U.S alone.

Carcinoembryonic antigen based breast cancer diagnosis is identified as the most lucrative application segment of the market. The market is driven by factors such as growing number of female population above 50 years, growing demand for Hormone Replacement Therapy (HRT) and cosmetic surgeries. Moreover, growing patient awareness levels and the presence of favorable government initiatives are expected to improve treatment rates over the forecast period.

North America was the largest regional market in 2014 owing to, the presence of high incidence rates, presence of favorable reimbursement framework, and high consumer awareness levels coupled with relatively higher healthcare expenditure levels.

Asia Pacific is anticipated to witness the most lucrative growth over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and improving patient awareness levels are some factors accounting for this rapid growth.

Key players operating in carcinoembryonic antigen market include Abbott Diagnostics, Quest Diagnostics, Roche Diagnostics, GenWay Biotech Inc. and Correlogic Systems, Inc.

For the purpose of this study, Grand View Research has segmented the carcinoembryonic antigen market on the basis of application, and region:

Carcinoembryonic Antigen Application Outlook (Revenue, USD Million, 2012 - 2022)

  • Colorectal cancer
  • Pancreatic cancer
  • Ovarian cancer
  • Breast cancer
  • Thyroid cancer
  • Others

Carcinoembryonic Antigen Regional Outlook (Revenue, USD Million, 2012 - 2022)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
  • MEA
    • South Africa
  • Latin America
    • Brazil
    • Mexico

Table of Content

Chapter 1: Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2: Executive Summary

Chapter 3: Carcinoembryonic Antigen Industry Outlook

  • 3.1. Market segmentation
  • 3.2. Market size and growth prospects
  • 3.3. Carcinoembryonic antigen-Market dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing prevalence of cancer
      • 3.3.1.2. Increasing geriatric population
      • 3.3.1.3. Increasing demand for minimally invasive diagnostic procedures
      • 3.3.1.4. Growing healthcare expenditure triggering the need for effective diagnostic procedure for cancer
      • 3.3.1.5. Increasing usage of combination biomarkers
      • 3.3.1.6. Usage of CEA at various stages of cancer
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Inefficiency to diagnose cancer at early stages
      • 3.3.2.2. Presence of complicated regulatory framework
  • 3.4. Key Opportunities Prioritized
  • 3.5. Industry analysis-Porter's
  • 3.6. Carcinoembryonic Antigen-PESTEL Analysis

Chapter 4: Carcinoembryonic Antigen Application Outlook

  • 4.1. Carcinoembryonic antigen revenue share by application, 2014 & 2022
  • 4.2. Colorectal cancer market
    • 4.2.1. Colorectal cancer market, 2012-2022(USD Million)
  • 4.3. Pancreatic cancer
    • 4.3.1. Pancreatic cancer market, 2012-2022(USD Million)
  • 4.4. Ovarian cancer
    • 4.4.1. Ovarian cancer market, 2012-2022(USD Million)
  • 4.5. Breast cancer
    • 4.5.1. Breast cancer market, 2012-2022(USD Million)
  • 4.6. Thyroid cancer
    • 4.6.1. Thyroid cancer market, 2012-2022(USD Million)
  • 4.7. Others
    • 4.7.1. Others market, 2012-2022(USD Million)

Chapter 5: Carcinoembryonic Antigen Regional Outlook

  • 5.1. Carcinoembryonic antigen market share, by region, 2014 & 2022
  • 5.2. North America
    • 5.2.1. North America market, by application, 2012-2022(USD Million)
    • 5.2.2. U.S.
    • 5.2.3. U.S. market, by application, 2012-2022(USD Million)
    • 5.2.4. Canada
    • 5.2.5. Canada market, by application, 2012-2022(USD Million)
  • 5.3. Europe
    • 5.3.1. Europe market, by application, 2012-2022(USD Million)
    • 5.3.2. Germany
    • 5.3.3. Germany market, by application, 2012-2022(USD Million)
    • 5.3.4. France
    • 5.3.5. France market, by application, 2012-2022(USD Million)
    • 5.3.6. Spain
    • 5.3.7. Spain market, by application, 2012-2022(USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific market, by application, 2012-2022(USD Million)
    • 5.4.2. Japan
    • 5.4.3. Japan market, by application, 2012-2022(USD Million)
    • 5.4.4. China
    • 5.4.5. China market, by application, 2012-2022(USD Million)
    • 5.4.6. India
    • 5.4.7. India market, by application, 2012-2022(USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America market, by application, 2012-2022(USD Million)
    • 5.5.2. Mexico
    • 5.5.3. Mexico market, by application, 2012-2022(USD Million)
    • 5.5.4. Brazil
    • 5.5.5. Brazil market, by application, 2012-2022(USD Million)
  • 5.6. MEA
    • 5.6.1. MEA market, by application, 2012-2022(USD Million)
    • 5.6.2. South Africa
    • 5.6.3. South Africa market, by application, 2012-2022(USD Million)

Chapter 6: Competitive Landscape

  • 6.1. Quest Diagnostics
    • 6.1.1. Company Overview
    • 6.1.2. Financial Performance
    • 6.1.3. Product Benchmarking
    • 6.1.4. Strategic Initiatives
  • 6.2. Roche Diagnostics
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Product Benchmarking
    • 6.2.4. Strategic Initiatives
  • 6.3. Abbott Diagnostics
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Product Benchmarking
    • 6.3.4. Strategic Initiatives
  • 6.4. GenWay Biotech Inc.
    • 6.4.1. Company Overview
    • 6.4.2. Financial Performance
    • 6.4.3. Product Benchmarking
    • 6.4.4. Strategic Initiatives
  • 6.5. Correlogic Systems, Inc.
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Product Benchmarking
    • 6.5.4. Strategic Initiatives

List of Tables

  • TABLE 1: Carcinoembryonic antigen - Industry summary & Critical Success Factors (CSFs)
  • TABLE 2: Global market , by application, 2012 - 2022 (USD Million)
  • TABLE 3: Global carcinoembryonic antigen market, by region, 2012 - 2022 (USD Million)
  • TABLE 4: Carcinoembryonic antigen - Key market driver analysis
  • TABLE 5: Global cancer incidences in 2012
  • TABLE 6: North America cancer incidences in 2012
  • TABLE 7: Europe cancer incidences in 2012
  • TABLE 8: Asia cancer incidences in 2012
  • TABLE 9: Africa cancer incidences in 2012
  • TABLE 10: Australia and New Zealand cancer incidences in 2012
  • TABLE 11: North America geriatric population (Over 60 Years) (Million) 2012 - 2022
  • TABLE 12: Europe geriatric population (Over 60 Years) (Million) 2012 - 2022
  • TABLE 13: Asia geriatric population (Over 60 Years) (Million) 2012 - 2022
  • TABLE 14: Latin America geriatric population (Over 60 Years) (Million) 2012 - 2022
  • TABLE 15: Africa geriatric population (Over 60 Years)(Million) 2012 - 2022
  • TABLE 16: Healthcare Expenditure, 2012
  • TABLE 17: Carcinoembryonic antigen - Key market restraint analysis
  • TABLE 18: North America market, by application, 2012 - 2022 (USD Million)
  • TABLE 19: U.S. carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 20: Canada market, by application, 2012 - 2022 (USD Million)
  • TABLE 21: Europe market, by application, 2012 - 2022 (USD Million)
  • TABLE 22: Germany market, by application, 2012 - 2022 (USD Million)
  • TABLE 23: France market, by application, 2012 - 2022 (USD Million)
  • TABLE 24: Spain carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 25: Asia Pacific market, by application, 2012 - 2022 (USD Million)
  • TABLE 26: Japan carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 27: China carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 28: India carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 29: Latin America market, by application, 2012 - 2022 (USD Million)
  • TABLE 30: Mexico market, by application, 2012 - 2022 (USD Million)
  • TABLE 31: Brazil carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 32: MEA carcinoembryonic antigen market, by application, 2012 - 2022 (USD Million)
  • TABLE 33: South Africa market, by application, 2012 - 2022 (USD Million)

List of Figures

  • FIG. 1: Carcinoembryonic antigen : Market segmentation
  • FIG. 2: Global Carcinoembryonic Antigen market, 2012 - 2022 (USD Million)
  • FIG. 3: Carcinoembryonic antigen : Market dynamics
  • FIG. 4: Global geriatric population, 2012 - 2022 (Million)
  • FIG. 5: Key opportunities prioritized
  • FIG. 6: Carcinoembryonic antigen market - Porter's analysis
  • FIG. 7: Carcinoembryonic antigen market - PESTEL analysis
  • FIG. 8: Carcinoembryonic antigen revenue share by application, 2014 & 2022
  • FIG. 9: Colorectal cancer market, 2012 - 2022 (USD Million)
  • FIG. 10: Pancreatic cancer market, 2012 - 2022 (USD Million)
  • FIG. 11: Ovarian cancer market, 2012 - 2022 (USD Million)
  • FIG. 12: Breast cancer market, 2012 - 2022 (USD Million)
  • FIG. 13: Thyroid cancer market, 2012 - 2022 (USD Million)
  • FIG. 14: Others market, 2012 - 2022 (USD Million)
  • FIG. 15: Carcinoembryonic antigen market share, by region, 2014 & 2022
  • FIG. 16: North America Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 17: U.S. Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 18: Europe Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 19: Germany Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 20: France Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 21: Spain Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 22: Asia Pacific Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 23: India Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 24: China Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 25: Japan Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 26: Latin America Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 27: Mexico Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 28: Brazil Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
  • FIG. 29: MEA Carcinoembryonic antigen market, 2012 - 2022 (USD Million)
Back to Top